Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)-Reference-Cited by-同舟云学术

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

Published:2017-01-24 Issue:4 Volume:116 Page:455-463
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Lindemann Kristina,Gibbs Emma,Åvall-Lundqvist Elisabeth,dePont Christensen Rene,Woie Kathrine,Kalling Marten,Auranen Annika,Grenman Seija,Hoegberg Thomas,Rosenberg Per,Skeie-Jensen Tone,Hjerpe Elisabet,Dørum Anne,Gebski Val,Kristensen Gunnar

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016435.pdf

Reference30 articles.

1. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30 (21): 2654–2663.

2. Batra S, Iosif CS (1996) Elevated concentrations of antiestrogen binding sites in membrane fractions of human ovarian tumors. Gynecol Oncol 60 (2): 228–232.

3. Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann Oncol 23 (8): 2020–2027.

4. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C (2004) Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90 (11): 2112–2117.

5. Cancer Therapy Evaluation Program (1992) Common Terminology Criteria for Adverse Events (CTCAE) Version 1.0.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature;The Oncologist;2024-05-20

2. Association Between Hormonal Maintenance Therapy and Progression-Free Survival in Advanced Epithelial Ovarian Cancer Patients: A Retrospective Study;Indian Journal of Gynecologic Oncology;2024-04-03

3. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements;International Journal of Molecular Sciences;2024-02-03

4. Systematic Review of the Literature on Multiple Co-occurring Symptoms in Patients Receiving Treatment for Gynecologic Cancers;Seminars in Oncology Nursing;2024-02

5. Systemische Therapie der epithelialen serösen Ovarialkarzinome;Deutsche Zeitschrift für Onkologie;2023-12